REPLIGEN CORP Number of Reportable Segments
REPLIGEN CORP (RGEN) reported Number of Reportable Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-07-29
- REPLIGEN CORP number of reportable segments for the quarter ending 2026-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- REPLIGEN CORP number of reportable segments for the quarter ending 2025-03-31 was 1.00 Segment.
- REPLIGEN CORP number of reportable segments for fiscal 2024 was 1.00 Segment.
- REPLIGEN CORP number of reportable segments for fiscal 2019 was 1.00 Segment, a 50.00% decline from fiscal 2018.
- REPLIGEN CORP number of reportable segments for fiscal 2018 was 2.00 Segment, a 0.00% change from fiscal 2017.
- REPLIGEN CORP number of reportable segments for fiscal 2017 was 2.00 Segment.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-07-29 | |||
| 2026-03-31 | 1.00 Segment 10-Q · filed 2026-05-06 | |||
| 2025-09-30 | 1.00 Segment 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | 1.00 Segment 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | 1.00 Segment 10-Q · filed 2025-04-29 | |||
| 2024-12-31 | 1.00 Segment 10-K · filed 2025-03-14 | |||
| 2019-12-31 | 1.00 Segment 10-K · filed 2020-02-26 | |||
| 2018-12-31 | 2.00 Segment 10-K · filed 2020-02-26 | |||
| 2017-12-31 | 2.00 Segment 10-K · filed 2018-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |